RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Valeo Pharma Stock

Valeo Pharma P/S 2024

Valeo Pharma P/S

0.15

Ticker

VPH.TO

ISIN

CA91915B1085

WKN

A2PLB4

As of Sep 18, 2024, Valeo Pharma's P/S ratio stood at 0.15, a -73.68% change from the 0.57 P/S ratio recorded in the previous year.

The Valeo Pharma P/S history

Valeo Pharma Aktienanalyse

What does Valeo Pharma do?

Valeo Pharma Inc is a pharmaceutical company that was founded in 2003. It is based in Montreal, Canada and its stocks are traded on the Toronto Stock Exchange. The company specializes in the development, manufacturing, and marketing of innovative pharmaceutical and medical products to help patients in Canada and around the world. Valeo Pharma's business model is based on identifying unmet medical needs, particularly in niche markets where there is a demand for innovative solutions. The company recognizes that there are difficulties for patients and healthcare professionals in finding specific medications suitable for their treatment needs in these niche markets. Valeo Pharma aims to fill this gap by developing innovative products tailored to the specific needs of patients and professionals, differentiating itself from other standard products. Valeo Pharma operates in two main business areas: Pharmaceuticals and OTC - Over-the-Counter. The pharmaceutical division of Valeo Pharma focuses on the development of drugs for the treatment of diseases that are currently inadequately treated. Their products in this area include drugs for the treatment of neurology, oncology, infectious diseases, dermatology, and psychiatry. Valeo Pharma's OTC division specializes in the development of products for self-medication and disease prevention. Their products in this area include pain relief products, cold and cough treatments, and general health support. Some of Valeo Pharma's key products include Blexten, an antihistamine for the treatment of seasonal and perennial allergic rhinitis as well as chronic idiopathic urticaria, and Redesca, a product for the prevention of blood clots and reducing the risk of thrombosis in patients with various medical conditions. Valeo Pharma has formed various partnerships with leading pharmaceutical companies around the world to bring its products to market. Through these partnerships, the company can expand its reach and offer exclusive products to its customers in different regions. Valeo Pharma is committed to research and development of new products that meet the needs of patients and healthcare professionals. The company invests in the development of active substances that treat diseases that are currently inadequately treated or have no effective medical treatments available. Overall, Valeo Pharma has established itself as a leading pharmaceutical company in Canada, focusing on providing innovative products to improve the health and well-being of patients. The company has a strong presence in the Canadian and international pharmaceutical industry and aims to expand its business through the development and marketing of innovative products and the formation of further strategic partnerships with pharmaceutical companies. Valeo Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Valeo Pharma's P/S Ratio

Valeo Pharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Valeo Pharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Valeo Pharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Valeo Pharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Valeo Pharma stock

What is the price-to-earnings ratio of Valeo Pharma?

The price-earnings ratio of Valeo Pharma is currently 0.15.

How has the price-earnings ratio of Valeo Pharma changed compared to last year?

The price-to-earnings ratio of Valeo Pharma has increased by -73.68% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Valeo Pharma high compared to other companies?

Yes, the price-to-earnings ratio of Valeo Pharma is high compared to other companies.

How does an increase in the price-earnings ratio of Valeo Pharma affect the company?

An increase in the price-earnings ratio of Valeo Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Valeo Pharma affect the company?

A decrease in the price-earnings ratio of Valeo Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Valeo Pharma?

Some factors that influence the price-earnings ratio of Valeo Pharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Valeo Pharma pay?

Over the past 12 months, Valeo Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Valeo Pharma is expected to pay a dividend of 0 CAD.

What is the dividend yield of Valeo Pharma?

The current dividend yield of Valeo Pharma is .

When does Valeo Pharma pay dividends?

Valeo Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Valeo Pharma?

Valeo Pharma paid dividends every year for the past 0 years.

What is the dividend of Valeo Pharma?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Valeo Pharma located?

Valeo Pharma is assigned to the '-' sector.

Wann musste ich die Aktien von Valeo Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Valeo Pharma from 9/18/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Valeo Pharma pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Valeo Pharma in the year 2023?

In the year 2023, Valeo Pharma distributed 0 CAD as dividends.

In which currency does Valeo Pharma pay out the dividend?

The dividends of Valeo Pharma are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Valeo Pharma

Our stock analysis for Valeo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Valeo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.